12:00 AM
 | 
Feb 23, 2009
 |  BioCentury  |  Emerging Company Profile

CT Atlantic: Reverse translation

Reverse translational medicine, the practice of developing therapeutics by studying patients who have a less severe disease state than others, has governed the development of vaccines against infectious disease for two centuries. CT Atlantic AG is applying the strategy to the identification and development of human antibodies to treat cancer.

The company, which spun out from the University of Zurich and The Ludwig Institute for Cancer Research last year, seeks patients with slower disease progression that suggests their immune systems are fighting off disease, then isolates and identifies the antibodies that could be responsible.

CEO Edward Stuart told BioCentury the approach is similar to that used by Neurimmune AG, which spun out of the university in 2006 to develop human-derived antibodies to treat Alzheimer's disease (AD). "But ours is based on different proprietary technology," he said. "It allows the cloning of antibodies directly from human B cells." Stuart is the former CEO...

Read the full 752 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >